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Background: Human farnesyl pyrophosphate synthase (FPPS) controls intracellular levels of farnesyl pyrophosphate,
which is essential for various biological processes. Bisphosphonate inhibitors of human FPPS are valuable
therapeutics for the treatment of bone-resorption disorders and have also demonstrated efficacy in multiple tumor
types. Inhibition of human FPPS by bisphosphonates in vivo is thought to involve closing of the enzyme’s
C-terminal tail induced by the binding of the second substrate isopentenyl pyrophosphate (IPP). This
conformational change, which occurs through a yet unclear mechanism, seals off the enzyme’s active site from the
solvent environment and is essential for catalysis. The crystal structure of human FPPS in complex with a novel
bisphosphonate YS0470 and in the absence of a second substrate showed partial ordering of the tail in the closed
conformation.
Results: We have determined crystal structures of human FPPS in ternary complex with YS0470 and the secondary
ligands inorganic phosphate (Pi), inorganic pyrophosphate (PPi), and IPP. Binding of PPi or IPP to the
enzyme-inhibitor complex, but not that of Pi, resulted in full ordering of the C-terminal tail, which is most notably
characterized by the anchoring of the R351 side chain to the main frame of the enzyme. Isothermal titration
calorimetry experiments demonstrated that PPi binds more tightly to the enzyme-inhibitor complex than IPP, and
differential scanning fluorometry experiments confirmed that Pi binding does not induce the tail ordering. Structure
analysis identified a cascade of conformational changes required for the C-terminal tail rigidification involving Y349,
F238, and Q242. The residues K57 and N59 upon PPi/IPP binding undergo subtler conformational changes, which
may initiate this cascade.
Conclusions: In human FPPS, Y349 functions as a safety switch that prevents any futile C-terminal closure and is
locked in the “off” position in the absence of bound IPP. Q242 plays the role of a gatekeeper and directly controls
the anchoring of R351 side chain. The interactions between the residues K57 and N59 and those upstream and
downstream of Y349 are likely responsible for the switch activation. The findings of this study can be exploited for
structure-guided optimization of existing inhibitors as well as development of new pharmacophores.
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The mevalonate pathway produces essential lipid mole-
cules, such as steroids and isoprenoids, in mammalian
cells. Occupying the first branching point of the mevalo-
nate pathway, farnesyl pyrophosphate synthase (FPPS)
catalyzes the sequential elongation of dimethylallyl pyro-
phosphate (DMAPP) to geranyl pyrophosphate (GPP)
and then to farnesyl pyrophosphate (FPP) via successive
condensation of two isopentenyl pyrophosphate (IPP)
molecules. The subsequent condensation of FPP and an-
other IPP unit in the pathway produces geranylgeranyl
pyrophosphate (GGPP). Covalent attachment of FPP and
GGPP (i.e. prenylation) is critical for the proper subcel-
lular localization and function of many proteins, includ-
ing small GTPases that regulate a wide variety of cellular
processes [1]. FPPS, therefore, is an attractive point of
pharmacological intervention. Bisphosphonate inhibitors
of FPPS, for instance, are widely used to treat a number
of bone disorders, such as Paget’s disease, hypercalcemia,
metastatic osteolysis, and osteoporosis currently [2].
Given the crucial roles of small GTPases in cancer de-
velopment [3-5], the ability of bisphosphonates to inhibit
FPPS and consequently the prenylation of these proteins
qualifies them also as potential cancer chemotherapeu-
tics. In addition, FPPS inhibition produces a secondary
anticancer effect via the accumulation of IPP, which
activates human γδ T immune cells [6,7]. Recent clinic-
al studies have demonstrated that bisphosphonate
drugs enhance the antitumor effects of various existing
therapeutics synergistically and improve survival in
patients with prostate cancer, breast cancer, and multiple
myeloma [8].
The mechanism by which bisphosphonates inhibit
human FPPS has been examined through char-
acterization of X-ray crystal structures. These com-
pounds bind at the DMAPP/GPP sub-pocket of the
enzyme’s active site, mimicking and competing against
these substrates [9,10]. The enzyme inhibition also
involves a sequence of conformational changes [9,10].
Bisphosphonate binding to the “open” form of the
enzyme drives a rigid body movement that closes the en-
trance to the DMAPP/GPP sub-pocket. This conform-
ational change fully shapes the second substrate binding
site, the IPP sub-pocket. Subsequent IPP binding to the
now “partially closed” enzyme induces the closing of
the 350KRRK353 C-terminal tail, which is disordered in
the absence of bound IPP, over the IPP entry site. These
C-terminal basic residues are essential for catalysis [11],
and upon closing secure the ligands into position and se-
quester the catalytic cavity from water. With the enzyme
in this “fully closed” state, replacement of the deeply
buried bisphosphonate inhibitor by a competing sub-
strate is very difficult, and hence the binding of the
bisphosphonate is deemed nearly irreversible. Theexceptional in vivo efficacy of bisphosphonate drugs,
therefore, is thought to arise in part from the
stabilization of the enzyme-inhibitor complex by the
binding of the accumulating substrate IPP [10]. Despite
its importance, however, the molecular details respon-
sible for the tail closure in human FPPS are largely
uncharacterized. That this conformational change is
induced by IPP is especially intriguing, as the ligand
does not make any direct contact with the 350KRRK353
tail when bound to the enzyme.
The bisphosphonates in current clinical use, such as
risedronate and zoledronate, are highly hydrophilic. The
resultant low membrane permeability, as well as their
extreme affinity for bone tissue, compromises the full
antineoplastic potential of these drugs. In an effort to
develop FPPS inhibitors with superior physicochemical
properties, we have recently identified potent and select-
ive 2-aminopyridine-based bisphosphonates (Figure 1A)
[12]. The crystal structure [PDB: 4DEM] of human FPPS
in complex with one of our new inhibitors, YS0470
(Figure 1B), revealed a series of novel interactions and
conformations in and around the active site cavity [12].
Most interestingly, the 350KRRK353 tail of the enzyme
was partially ordered, with its main chain covering over
the IPP sub-pocket but its side chains fully flexible [12].
This finding provided the first report of such a conform-
ational state in human FPPS and raised a question
whether the IPP sub-pocket in the enzyme-YS0470 com-
plex is still accessible to a ligand. In order to address this
question, we have determined crystal structures of
human FPPS in ternary complex with YS0470 and the
secondary ligands inorganic phosphate (Pi), inorganic
pyrophosphate (PPi), and IPP. Prior to the present com-
munication there have been only two IPP-bound human
FPPS structures available, determined independently but
both co-bound with zoledronate [9,10], and none with
bound PPi. Crystal structure analysis and complemen-
tary isothermal titration calorimetry (ITC) and differen-
tial scanning fluorometry (DSF) experiments reveal new
insights into the details of the ligand-induced conform-
ational changes in human FPPS and suggest a mechan-
ism for the enzyme’s C-terminal tail closure. A better
understanding of the human FPPS tail closure may help
develop new classes of anticancer drugs that function by
targeting this crucial conformational change.
Methods
Crystal-soaking and data collection
Expression and purification of recombinant human
FPPS, as well as crystallization of the enzyme-YS0470
binary complex, were carried out as previously described
[12]. Aqueous solutions of Pi and PPi were prepared at
5 mM concentration. IPP was prepared at 4.5 mM con-




















Figure 1 Novel bisphosphonate inhibitors of human FPPS. (A) General structure of 2-aminopyridine-based bisphosphonate inhibitors (see ref.
[12] for the complete list of functional groups at the substitution site). (B) Compound YS0470.
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containing two to three single crystals. The coverslips
holding the ligand-added drops were resealed over the
same reservoir wells in the original crystallization tray,
which was then incubated overnight to ensure maximal
diffusion of the ligand into the crystals. Diffraction data
were collected from a single crystal for each ligand
under a nitrogen cryo-stream as 0.5° oscillation images
by using a Rigaku RUH3R X-ray generator with a rotat-
ing Copper anode and a Rigaku R-AXIS IV++ area
detector.
Data processing and structure refinement
The diffraction images were processed with HKL2000






Unit cell dimension (Å) a = b = 110.98, c = 66.79
Resolution range (Å) 50.0-2.02 (2.05-2.02)
Redundancy 26.4 (24.1)






No. protein atoms 2,705
No. ligand atoms 31
No. ion atoms 3
No. solvent atoms 132
R.m.s. deviations
Bond length (Å) 0.018
Bond angle (°) 1.8
Values in parentheses are for the highest resolution shell.Fourier methods with the ligand-omitted structure of the
human FPPS-YS0470 binary complex [PDB: 4DEM] as
an input model. These structures were further improved
through iterative rounds of manual and automated re-
finement with COOT [14], PHENIX [15], and REFMAC5
[16]. The final models of the ternary complexes have
been deposited into the Protein Data Bank. Data collec-
tion and refinement statistics, as well as the PDB ID for
each structure, is presented in Table 1.
Structure analysis
Structure analysis and model representation were per-
formed with the molecular modeling and visualization
programs COOT [14] and PyMOL (version 1.3 Schrö-
dinger, LLC.). Information on the structure models used4H5D 4H5E
YS0470, PPi YS0470, IPP
P41212 P41212
a = b = 111.53, c = 66.24 a = b = 111.24, c = 65.65
50.0-2.02 (2.05-2.02) 50.0-2.05 (2.09-2.05)
28.2 (27.9) 27.3 (26.2)
100 (100) 100 (100)
59.9 (7.7) 47.7 (6.9)
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ligands, is summarized in Table 2.
Isothermal titration calorimetry
ITC experiments were performed with a VP-ITC titra-
tion calorimeter from GE Healthcare. The human FPPS
sample was prepared at 50 μM concentration in the
presence of 150 μM YS0470 and 200 μM MgCl2 in a
buffer containing 10 mM HEPES (pH 7.5), 500 mM
NaCl, 2 mM β-mercaptoethanol, and 5% glycerol. Ligand
solutions were prepared in the same buffer at concentra-
tions ranging from 0.1 to 1 mM. Titrations were carried
out at 30 °C, and the data were analyzed with the Origin
7 software provided by the manufacturer.
Differential scanning fluorometry
The samples were prepared to the final volume of 40 μL
in the following concentrations: 4 μM protein, 10 mM
HEPES (pH 7.5), 10 mM NaCl, 5 mM MgCl2, and 5×
SYPRO Orange dye (Invitrogen, commercial stock solu-
tion is 5000×). When added, the final concentration of
YS0470 was 40 μM, and those of the secondary ligands
(Pi, PPi, and IPP) were up to 400 μM. All samples were
prepared in triplicate. Fluorescence was measured by
using an iCycler RT-PCR instrument with an iQ5 de-
tector (Bio-Rad) while heating the samples in a gradient
from 30 to 90°C in 0.5°C steps every 10 s. The midpoint
temperature of the unfolding transition (Tm) was calcu-
lated by using the software package Bio-Rad iQ5.
Results and discussion
Structures of the human FPPS ternary complexes
We were able to obtain crystals of human FPPS in tern-
ary complex with different ligands. X-ray diffraction ana-
lysis of these crystals has clearly identified the secondaryTable 2 Human FPPS structure models analyzed in this study
PDB ID Res. (Å) Bisphosphonate inhibitora Othe
2F7M 2.30 - -
2F8C 2.20 Zoledronate Pi
2F8Z 2.60 Zoledronate IPP
1YV5 2.00 Risedronate Pi
1ZW5 2.30 Zoledronate IPP
3N45 1.88 Zoledronate Pi, F
3N46 2.35 Zoledronate Pi, N
4DEM 1.85 YS0470 -
4H5C 2.02 YS0470 Pi
4H5D 2.02 YS0470 PPi
4H5E 2.05 YS0470 IPP
aAll bisphosphonates are bound with Mg2+ ions.
bAllosteric inhibitors.
Please note that in the PDB structures 1YV5, 1ZW5, and 4DEM, the amino acids are
The C-terminal tail KRRK residues in these structures are thus numbered from 364 tligands (i.e. Pi, PPi, and IPP) bound in the IPP sub-
pocket, as well as the inhibitor YS0470 in the DMAPP/
GPP sub-pocket. Co-binding of the secondary ligands
did not affect the pre-bound inhibitor, as the binding lo-
cation and orientation of this inhibitor, as well as its
interaction with the enzyme, remain unchanged in the
three ternary complexes from those previously observed
in the binary complex [PDB: 4DEM] [12].
The overall structure of the human FPPS-YS0470-Pi
ternary complex is very similar to that of the binary com-
plex, with the backbone RMSD value of 0.19 Å. The Pi
molecule, found at the previously described IPP binding
site [9,10], forms direct polar contacts with the main chain
of K57 and the side chain of R113 (Figure 2A). In addition,
the ligand is further stabilized by an intricate network of
water-mediated hydrogen bonds involving a number of
residues including N59, R60, E93, and R112 (Figure 2A).
The space occupied by Pi in the ternary complex instead
accommodates a water molecule with a high B-factor in
the binary complex. Another difference between the two
structures is the absence of two ordered water molecules
(shown as yellow spheres in Figure 2A) near the C-
terminal residue K353 in the ternary complex. The reason
for this discrepancy is unclear, but these water molecules
may contribute to the closing of the 350KRRK353 tail by
bridging hydrogen bond interactions between K353 and
the residues R112, R113, and T255 (Figure 2A).
The 350KRRK353 tail of the Pi-bound ternary complex
is similar to that of the binary complex, with flexible and
thus undefined side chains (Figure 2B). Although the
backbone atoms of the tail could be modeled in and
refined without much difficulty during the structure re-
finement process, the electron density around this area
was weak (Figure 2B), suggesting partial ordering. A dir-






BS_04b Partially closed [21]
OV_980b Partially closed [21]
Partially closed [12]
Partially closed Current report
Fully closed Current report
Fully closed Current report
numbered with an offset of 14 compared to the rest of the structures.
o 367.
Figure 2 Structures of human FPPS ternary complexes at the IPP sub-pocket and the 350KRRK353 tail regions. (A) The cavity of the IPP
sub-pocket is filled with ordered water molecules as well as the bound Pi. The water molecules, which are displayed as red spheres, neutralize
the surrounding charged residues and also provide structural support via hydrogen bonds (yellow dashes) to this flexible region. The yellow
spheres represent the two water molecules present in the FPPS-YS0470 binary complex [PDB: 4DEM] but not in the FPPS-YS0470-Pi ternary
complex, and the grey dashes show their interactions with the adjacent entities. (B) The 350KRRK353 tail is in the same conformation as that
previously seen in the FPPS-YS0470 binary complex. Compound YS0470 and Pi are bound deeper in the active site and too far from the
C-terminal region to have any direct interaction with the tail residues. (C and E) The phosphate groups of the bound PPi and IPP superpose very
well. Other bound water molecules and water-mediated hydrogen bonding interactions are omitted for clarity. We have sub-divided the PPi
binding site into the alpha- and beta-sites for easier description. (D and F) The 350KRRK353 tail is in the fully closed conformation in the both
complexes. The grey meshes represent simulated-annealing omit (Fo-Fc) maps contoured at 3.0 sigma level. Carbon atoms are represented in
green, cyan, and magenta, for the FPPS-YS0470-Pi, FPPS-YS0470-PPi, and FPPS-YS0470-IPP ternary complexes, respectively. The color schemes for
other atoms (red for oxygen; blue for nitrogen; and orange for phosphorous) are consistent throughout all the figures.
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hydrogen bond between the main chain nitrogen of
D251 and the main chain oxygen of R352, may be re-
sponsible for the partial ordering of the tail at this loca-
tion (Figure 2B). The water molecule mediating the
latter hydrogen bonding interaction is well ordered, as
also seen in the binary complex previously [12]. The side
chain nitrogen of Q242 is within the hydrogen bonding
range to the main chain oxygen of R351 (Figure 2B), but
such an interaction is not likely, as the angle between
the hydrogen donor and acceptor atoms is suboptimal in
the current conformational state.
The overall structures of the PPi- and IPP-bound tern-
ary complexes are more similar to each other (RMSD:
0.16 Å) than to those of the binary complex and the Pi-
bound ternary complex (RMSD: 0.25-0.31 Å). The PPi
and IPP-binding sites fully overlap the Pi-binding site,
which we refer to as the beta phosphate site (Figure 2A,
C, and E). The space that accommodates the alpha phos-
phate moiety of IPP, or the alpha phosphate site
(Figure 2E), is instead occupied by a single water mol-
ecule in both the Pi-bound ternary complex (Figure 2A)
and the binary complex [PDB: 4DEM]. The phosphate
moiety at the alpha site provides additional charge
interactions with the residues R60 and Q112 in both the
PPi- and IPP-bound complexes (Figure 2C and E). The
isopentenyl tail of the bound IPP ligand extends toward
the bisphosphonate inhibitor YS0470 (Figure 2E), dis-
placing water molecules otherwise present in the area
(Figure 2A and C). These water molecules in the PPi-
bound complex form a tight set of hydrogen bonds con-
necting the PPi and bisphosphonate molecules and the
residues Y204 and Q240 (Figure 2C). Other water mole-
cules and water-mediated interactions around the sec-
ondary ligands in the PPi- and IPP-bound complexes are
analogous to those in the Pi-bound ternary complex and
the binary complex.
The 350KRRK353 tail in both the PPi- and IPP-bound
ternary complexes is closed and fully ordered, as evi-
denced by the clearly defined electron density
(Figure 2D and F), as well as the average B-factors of the
four C-terminal residues (Additional file 1: Table S1).
This conformational state is most notably characterized
by the rigidification of R351 (Figure 2D and F), as also
observed in the human FPPS-zoledronate-IPP ternary
complex [PDB: 1ZW5 and 2F8Z] previously [9,10]. All
three side chain nitrogen atoms of R351 are involved in
either direct or water-mediated hydrogen bonding to the
neighbouring residues F239, Q242, D243, and K353,
thereby holding the tail tightly in position (Figure 2D
and F). The side chain of K57 in the PPi- and IPP-bound
complexes is also more ordered compared to that of the
Pi-bound complex, forming hydrogen bonds to the sec-
ondary ligand PPi or IPP and the terminal oxygen atomof K353 (Figure 2B, D, and F). The structures of our
PPi- and IPP-bound enzyme complexes thus represent
the “fully closed” state, in contrast to the structure of
our “partially closed” Pi-bound complex (summarized in
Table 2).
Binding of Pi, PPi, and IPP to the human FPPS-YS0470
binary complex
In this work, we have shown for the first time that the
binding of PPi induces the full closure of the 350KRRK353
tail in human FPPS. This finding is interesting because
PPi, unlike IPP, is not a substrate for the enzyme. The
PPi molecule in our ternary complex does not represent
a product state either, although the FPPS reaction pro-
duces PPi, as it is in the IPP sub-pocket. The transfer of
the allylic chain in this reaction, which is from DMAPP
or GPP to IPP [17,18], should leave the product
PPi in the DMAPP/GPP sub-pocket. The PPi-induced
C-terminal tail closure also demonstrates that the pres-
ence of the isopentenyl moiety on the secondary ligand
is not a necessary condition for this conformational
change in the human FPPS ternary complex. Rather, it is
the phosphate moiety occupying the alpha phosphate
site that is decisively responsible for the tail closure of
the protein. The structure of our Pi-bound ternary com-
plex, as well as those previously determined by others
(Table 2), indicates that the occupancy of the beta phos-
phate site by a single phosphate group alone cannot in-
duce this conformational change.
A crucial implication of the PPi-induced C-terminal
tail closure in human FPPS is that PPi, which is a preva-
lent cellular metabolite, may have a relevant role in the
inhibition of the enzyme in vivo. Based on the structures
of our PPi and IPP-bound ternary complexes, which are
both in the fully closed state, PPi would at least be
equally effective as IPP in stabilizing the protein-
inhibitor complex, if not better. The inner surface of the
IPP sub-pocket of FPPS is highly hydrophilic, and
the hydrophobic isopentenyl tail of IPP is forced to
stack against a number of hydrophilic side chain func-
tional groups upon its binding to the enzyme. These
interactions may be beneficial for the catalysis and the
subsequent release of the product in the isoprenoid
elongation reaction, but not for stabilizing the enzyme-
bisphosphonate complex in the closed state. With PPi
binding, on the other hand, the water molecules bound
in place of the isopentenyl tail of IPP may further
stabilize the protein-inhibitor complex by linking the
ligands and the surrounding residues. These water
molecules play an especially important role in the bind-
ing of our inhibitor YS0470, which lacks the hydroxyl
‘hook’ present in most of the currently used bisphospho-
nate drugs, by making up for the missing polar inter-
action seen in the presence of this functional group
Figure 3 Ligand binding to human FPPS. (A) The active site structures of the FPPS-YS0470-PPi complex (cyan) and the FPPS-zoledronate-IPP
complex (white) [PDB: 1ZW5] are presented superimposed. The IPP molecule in the zoledronate complex is not shown for clear visualization of
the bisphosphonates. The hydroxyl ‘hook’ of the bound zoledronate is circled in red. This functional group forms a hydrogen bond with the side
chain of D243, which is represented as a grey dashed line in the illustration. The orange dashed lines represent stacking interactions between
YS0470 and the residues F99 and Q171. (B) ITC isotherms for the binding of PPi and IPP to the human FPPS-YS0470 complex. Three independent
experiments were carried out for each ligand. The binding parameters were determined from each data set by using a one-site model. The
reported values are Mean ± SEM from the three experiments. T = 303.15 kelvin. (C) A bar graph showing melting temperatures of human FPPS in
various ligand-bound states measured by DSF. In order to ensure complete complex formation, YS0470 and the secondary ligands were added at
10- and 100-fold molar excess of the protein, respectively.
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our series of bisphosphonates is advantageous for the
purpose of targeting non-bone tissues, because the pres-
ence of this substituent in a bisphosphonate increases its
affinity for bone mineral [19,20].
In order to confirm that PPi indeed forms a tighter
complex with human FPPS and YS0470 than IPP, we
have carried out ITC experiments in which the second-
ary ligands were titrated into a protein sample pre-
saturated with the inhibitor and magnesium ions. The
dissociation constant (Kd) was determined to be lower
for PPi (Figure 3B), indicating that PPi-binding is indeed
stronger than IPP-binding. The higher binding affinity of
PPi is due to a more favorable (more negative) enthalpy
change (ΔH, Figure 3B), which corroborates our predic-
tion that the strength of interactions between the ligand
and the protein-inhibitor complex is greater for PPi. The
entropic component of binding (TΔS), on the other
hand, was shown to be more favorable (less negative) for
IPP (Figure 3B), although not sufficient to fully counter
the enthalpic effect. The difference in the entropy
change is likely due to desolvation effects: more water
molecules would be released from the binding site and
the ligand itself upon IPP-binding, resulting in greater
degrees of freedom in the system. In contrast to the
solvation entropy change, the conformational entropy
change should be slightly less favorable for IPP binding,
as IPP with more rotatable bonds within the molecule
than PPi would lose greater degrees of conformational
freedom upon binding. Changes in protein conform-
ational entropy resulting from ligand binding should be
similar between PPi and IPP, based on our structural
data.
We have also examined the binding of Pi to the
human FPPS-YS0470 complex by ITC, but could not re-
liably determine its energetic profile due to a low heat
signal. The weak thermodynamic signature likely reflects
low affinity binding, as well as the absence of a major
conformational change (e.g., the C-terminal tail closure)
induced by the binding. Complimentary DSF experi-
ments indeed confirmed the lack of any significant con-
formational change induced by Pi binding. As seen in
Figure 3C, the Tm of human FPPS increases ~10°C in
the presence of YS0470, indicating that the enzyme is
more thermally stable in its partially closed state than in
the open state. Addition of the secondary ligands PPi
and IPP further stabilizes the enzyme, likely via the full
closure of the enzyme, whereas Pi does not provide any
additional thermal protection, indicating the lack
thereof. It is interesting here that the human FPPS com-
plex shows a higher Tm in the presence of IPP (80°C)
than with PPi (75°C). These values are seemingly at odds
with the results of the ITC experiments, suggesting that
IPP forms a tighter complex with human FPPS andYS0470 than PPi. However, as described earlier, PPi
binding results in a more favorable enthalpy change
(ΔH) than IPP binding but a less favorable entropy
change (ΔS). The entropic effects of course become
increasingly pronounced for ligand binding as the
temperature rises. Based on the ΔH and ΔS values deter-
mined from the ITC experiments (Figure 3B), the bind-
ing of IPP to the human FPPS-YS0470 complex becomes
more favorable than that of PPi only at temperatures
above ~70°C.
Mechanistic details of the C-terminal tail closure in
human FPPS
As mentioned previously, the molecular details respon-
sible for the tail closing action in human FPPS are
largely unknown, despite its functional importance.
What is clear, however, is that the role of the R351 side
chain is absolutely critical in the full closing of the
350KRRK353 tail. This side chain not only anchors the
residue itself to the 221G-E247 helix, one of the longest
central helices of human FPPS, but also helps hold the
last residue K353 in position by providing a salt bridge
(as seen in Figure 2D and F). The electron density
observed for our Pi-bound complex has demonstrated
that the side chain of R351 can still be entirely flexible,
while the main chain of the C-terminal tail is partially
ordered and structured (as seen in Figure 2B). This find-
ing suggests that the recruitment of the tail to the ap-
proximate region occurs first, where the tail is held
loosely by other interactions perhaps involving those
described earlier (Figure 2A and B), prior to the rigidifi-
cation of the R351 side chain.
Analysis of our FPPS structures suggests that proper
positioning and ordering of the R351 side chain also
requires a series of preceding conformational changes in
the residues Q242, F238, and Y349. In the absence of
bound PPi/IPP, Q242 forms a hydrogen bond to a nearby
water molecule and together with it blocks the anchor-
ing of the R351 side chain to the 221G-E247 helix
(Figure 4A). The conformational change in Q242, in
turn, requires a ~20° rotational translocation of the F238
side chain, which is prohibited due to steric hindrance
by the Y349 side chain in the absence of PPi/IPP
(Figure 4A). In this anchor-blocking conformation, the
Y349 side chain is stacked tightly in position between
the side chains of F238 and Y322, and is further stabi-
lized via a polar interaction with the residue S321
(Figure 4A). In the anchor-accepting conformation, on
the other hand, the side chain of Y349, as well as those
of the adjacent aromatic residues F238 and Y322, has
significantly greater freedom of movement, as evident
from the electron density maps and the refined B-factors
(Additional file 2: Figure S1). The above findings suggest
that Y349, lying upstream in the cascade of these
Figure 4 Residues involved in the human FPPS C-terminal tail closure. (A) The structures of the FPPS-YS0470-Pi (green) and FPPS-YS0470-PPi
(cyan) complexes are superimposed. The conformational changes that occur prior to the rigidification of the R351 side chain are indicated with
black arrows. The residues Y349, F238, and Q242 are in the anchor-blocking conformation in the Pi-bound complex and in the anchor-accepting
conformation in the PPi-bound complex. (B) A schematic representation of the Y349 switch activation: the K57 side chain rigidifies and attracts
the C-terminal tail; N59 interacts with K347 via a water molecule; and the Y349 side chain rotates out due to the torsion created by these two
forces.
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which is normally locked in the “off” mode to prevent
any futile C-terminal tail closure. Q242, on the other
hand, plays the role of a gatekeeper in the enzyme,which directly controls the anchoring of R351. The
greater structural freedom of the three aromatic residues
(i.e. F238, Y322, and Y349) in the fully closed form of
the enzyme may contribute to compensate for the
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ordering of the tail.
Despite the many currently available FPPS structures,
it is still unclear how PPi/IPP binding turns on the Y349
switch in the human enzyme. This process is particularly
intriguing, as the binding site for the secondary ligands
is quite far (> 10 Å) from the tyrosine residue, whose
conformational change is yet very drastic (i.e. ~80° rota-
tion of the side chain). Comparison of the new ternary
structures has allowed us to propose the following puta-
tive mechanism. Simultaneous occupancy of the alpha
and beta phosphate sites by a pyrophosphate group in
the IPP sub-pocket rigidifies the otherwise flexible K57
side chain (Figure 4B). The side chain of K57 in turn
attracts the 350KRRK353 tail, which is partially present
and/or structured in the vicinity, by forming a salt bridge
with the terminal carboxyl group (Figure 4B). This
~0.7 Å shift of the tail is not likely a result of a modeling
artefact, as it is accompanied by a similar movement in
the adjacent 250G-T255 helix-turn segment (Figure 4B),
of which such a shift induced by IPP binding has been
also observed in the zoledronate-bound enzyme com-
plexes [PDB: 2F8C, 2F8Z, and 1ZW5]. In addition to the
rigidification of the K57 side chain, PPi/IPP binding
results in a ~10° angular shift of the N59 side chain,
which is translated into a similar movement of the resi-
dues K347 and I348 via a water molecule (Figure 4B).
Interestingly, no water molecule has ever been observed
at this position in human FPPS, except in the presence
of bound PPi or IPP. These PPi/IPP-induced interactions
between K57 and the residues downstream of Y349, and
between N59 and those immediately upstream, may cre-
ate a torque strong enough to rotate the Y349 side chain
out of its “off” conformation (Figure 4B).
Implications of the C-terminal tail closure on drug
development
The activity of human FPPS involves a dynamic behav-
ior, in which the enzyme alternates between the
substrate-binding (open/partially closed) and catalytic
(fully closed) states. As biasing this equilibrium either
way results in enzyme inhibition, compounds that can
inhibit the enzyme’s C-terminal tail closure can also in-
hibit its function. The non-bisphosphonate inhibitors of
human FPPS identified in a recent fragment-based
screening study [21] are of much relevance. These inhi-
bitors, which act by binding to an allosteric site adjacent
to the IPP sub-pocket, have completely different chem-
ical scaffolds from the existing bisphosphonate drugs
and thus a great potential as chemotherapeutic agents to
target non-bone tissues. The mechanism of inhibition by
this series of compounds is thought to involve a car-
boxylic functional group that interferes with the binding
of IPP by electrostatic repulsion [21]. In addition, someof these compounds that are bulkier (e.g., FBS_04 and
NOV_980, in the PDB structures 3N45 and 3N46, re-
spectively) directly inhibit the closing of the C-terminal
tail by steric hindrance [21]. Intriguingly, the location of
the newly identified allosteric pocket is such that N59
and K347, which mediate the communication between
the IPP sub-pocket and the tyrosine switch according to
our proposed mechanism (as seen in Figure 4B), form
opposite walls of this pocket. We predict that, therefore,
compounds which occupy the allosteric pocket of
human FPPS would inhibit its tail closure even in the
presence of bound IPP, by disrupting the interaction be-
tween N59 and K347. Based on this prediction, then,
elimination of the carboxylic group from the aforemen-
tioned allosteric inhibitors should not affect their ability
to inhibit the enzyme, although their binding affinity
would likely be changed. Removal of this highly charged
moiety or its replacement with a preferable functional
substituent may improve the pharmacokinetic properties
of these compounds, proving the usefulness of the novel
insights regarding the human FPPS tail closure provided
in the present communication. Alternatively, by taking
advantage of the new information, it may be possible to
develop inhibitors that can trigger the C-terminal tail
closure without IPP and lock the enzyme in the fully
closed state, as the concept for such inhibitors was pro-
posed recently [22].
Conclusions
We have previously shown that the 350KRRK353 tail in
the human FPPS-YS0470 binary complex is only partially
structured. Here we have demonstrated that the binding
of PPi or IPP to the IPP sub-pocket of the binary com-
plex, but not that of Pi, fully structures the enzyme’s tail,
which seals off the active site from the solvent environ-
ment and thereby stabilizes the protein-inhibitor com-
plex. By examining the human FPPS structures
presented in this report and those previously determined
by others, we have also identified key residues and inter-
actions responsible for this C-terminal rigidification. The
tail closure is controlled by a safety mechanism involving
the residue Y349, which is trapped in the “off” conform-
ation in the absence of bound PPi/IPP. Turning on the
tyrosine switch allows the gatekeeper Q242 to take on
the anchor-accepting conformation, which in turn
results in the clamping of R351 to the enzyme’s main
frame. The rigidification of the anchor arginine is likely
the final step in the sequence of events required for the
complete closure of the 350KRRK353 tail. The process by
which PPi/IPP-binding activates the tyrosine switch is
not entirely clear, but we speculate that it involves subtle
rotations and shifts initiated in the residues around the
IPP sub-pocket and transmitted to those directly preced-
ing and succeeding the tyrosine switch. The structures
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useful for optimizing clinically relevant inhibitors. Fur-
ther, the novel insights with respect to the enzyme’s tail
closing mechanism may help develop entirely new
pharmacophores.Additional files
Additional file 1: Table S1. Average B-factors for the overall structure
and the four C-terminal residues of human FPPS complexes.
Additional file 2: Figure S1. Electron density maps and average
B-factors for the residues involved in the human FPPS tail closure. The
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